Gaston Picchio - Arbutus Biopharma Chief Officer
| ABUS Stock | USD 3.42 0.09 2.56% |
Insider
Gaston Picchio is Chief Officer of Arbutus Biopharma Corp
| Age | 61 |
| Address | 701 Veterans Circle, Warminster, PA, United States, 18974 |
| Phone | 267 469 0914 |
| Web | https://www.arbutusbio.com |
Arbutus Biopharma Management Efficiency
The company has return on total asset (ROA) of (0.3283) % which means that it has lost $0.3283 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6781) %, meaning that it created substantial loss on money invested by shareholders. Arbutus Biopharma's management efficiency ratios could be used to measure how well Arbutus Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.53 in 2024. Return On Capital Employed is likely to drop to -0.67 in 2024. At this time, Arbutus Biopharma's Other Current Assets are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 165.2 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 11.8 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Juli Miller | Adaptimmune Therapeutics Plc | N/A | |
| Cyndi Tolman | ADMA Biologics | N/A | |
| PharmD BCOP | ADMA Biologics | N/A | |
| Bertrand Esq | Adaptimmune Therapeutics Plc | 57 | |
| Richard MD | Corvus Pharmaceuticals | 73 | |
| Sbastien Desprez | Adaptimmune Therapeutics Plc | N/A | |
| Denise Mueller | Affimed NV | 54 | |
| Angus Smith | Affimed NV | 42 | |
| Kaitlin Kestenberg | ADMA Biologics | 37 | |
| Helen MBA | Adaptimmune Therapeutics Plc | 57 | |
| Uwe Reusch | Affimed NV | N/A | |
| Joanna Brewer | Adaptimmune Therapeutics Plc | 48 | |
| ACA BA | Adaptimmune Therapeutics Plc | 54 | |
| CPA CPA | ADMA Biologics | 52 | |
| Michael Least | ADMA Biologics | N/A | |
| Margaret Henry | Adaptimmune Therapeutics Plc | N/A | |
| Alan Esq | Corvus Pharmaceuticals | N/A | |
| MD FACP | Corvus Pharmaceuticals | 64 | |
| Michael Goldstein | ADMA Biologics | N/A | |
| Alexander Fudukidis | Affimed NV | N/A | |
| Pr Little | Affimed NV | N/A | |
Management Performance
| Return On Equity | -0.68 | ||||
| Return On Asset | -0.33 |
Arbutus Biopharma Corp Leadership Team
Elected by the shareholders, the Arbutus Biopharma's board of directors comprises two types of representatives: Arbutus Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Arbutus. The board's role is to monitor Arbutus Biopharma's management team and ensure that shareholders' interests are well served. Arbutus Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Arbutus Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| BA Esq, General Officer | ||
| Gaston Picchio, Chief Officer | ||
| Lisa Caperelli, Vice Relations | ||
| David CPA, CFO Officer | ||
| William Collier, CEO Pres | ||
| Elizabeth Howard, Gen VP | ||
| Michael McElhaugh, Interim CoFounder | ||
| Michael Sofia, Chief Officer | ||
| BA JD, Sec | ||
| Karen MD, Chief Officer | ||
| Shannon SPHR, Vice Resources |
Arbutus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Arbutus Biopharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.68 | ||||
| Return On Asset | -0.33 | ||||
| Operating Margin | (13.05) % | ||||
| Current Valuation | 538.77 M | ||||
| Shares Outstanding | 189.49 M | ||||
| Shares Owned By Insiders | 22.22 % | ||||
| Shares Owned By Institutions | 53.82 % | ||||
| Number Of Shares Shorted | 6.54 M | ||||
| Price To Earning | (1.16) X | ||||
| Price To Book | 6.22 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Arbutus Stock Analysis
When running Arbutus Biopharma's price analysis, check to measure Arbutus Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arbutus Biopharma is operating at the current time. Most of Arbutus Biopharma's value examination focuses on studying past and present price action to predict the probability of Arbutus Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arbutus Biopharma's price. Additionally, you may evaluate how the addition of Arbutus Biopharma to your portfolios can decrease your overall portfolio volatility.